Related Experiment Video
Updated: Aug 21, 2026
Surgical Porcine Model of Chronic Myocardial Ischemia Treated by Exosome-laden Collagen Patch and Off-pump Coronary Artery Bypass Graft
Published on: September 15, 2023
Does clopidogrel increase blood loss following coronary artery bypass surgery?
Michael W A Chu1, Steve R Wilson, Richard J Novick
1Division of Cardiac Surgery, London Health Sciences Centre, London, Ontario, Canada.
Insights
Discontinuing clopidogrel (Plavix) more than 4 days before coronary artery bypass surgery is associated with reduced blood loss and fewer transfusions. This timing is crucial for improving patient outcomes after cardiac surgery.
Area of Science:
- Cardiovascular Surgery
- Pharmacology
- Transfusion Medicine
Background:
- Clopidogrel (Plavix) is a key antiplatelet medication used in acute coronary syndromes and percutaneous coronary interventions.
- Its antiplatelet effects may increase bleeding risk in patients undergoing coronary artery bypass surgery.
Purpose of the Study:
- To evaluate the impact of clopidogrel timing relative to coronary artery bypass grafting (CABG) on perioperative blood loss and transfusion requirements.
- To identify if clopidogrel use within 4 days of surgery is an independent risk factor for adverse outcomes.
Main Methods:
- Prospective data collection from 312 urgent/emergent CABG patients.
- Stratification into three groups based on clopidogrel discontinuation timing: within 4 days, 5-8 days, and >8 days or never used.
- Comparison of blood loss, transfusion needs, reoperation rates, and length of stay.
Main Results:
- Patients receiving clopidogrel within 4 days of CABG experienced significantly higher chest tube blood loss (1044 mL vs. ~550 mL) and blood product transfusions (12.2 U vs. ~2.6 U).
- Reoperation for bleeding occurred in 14.6% of the early clopidogrel group versus <3% in others (p=0.002).
- Clopidogrel within 4 days was an independent predictor of increased transfusion requirements, longer ICU stay, and overall hospital stay.
Conclusions:
- Clopidogrel use within 4 days of coronary bypass surgery is linked to substantial increases in blood loss and reoperation for bleeding.
- Early clopidogrel administration is an independent risk factor for higher transfusion needs and prolonged hospital and ICU stays following CABG.
Background:
Clopidogrel (Plavix) is a potent inhibitor of platelet aggregation used concomitantly with percutaneous coronary interventions and in patients with acute coronary syndromes. Its favorable effects on preventing thrombus formation may have deleterious effects on hemostasis in patients undergoing coronary surgery.
Methods:
Data were collected prospectively on 312 consecutive urgent or emergent coronary artery bypass patients from July 1999 through April 2001 at a tertiary care center. Patients were stratified into three groups: clopidogrel within 4 days of operation (n = 41), clopidogrel continued until 5 to 8 days before operation (n = 39), and clopidogrel discontinued more than 8 days before operation or were never taking clopidogrel (n = 232).
Results:
Preoperative and intraoperative characteristics were similar among all groups. Mediastinal and pericardial chest tube losses in the first 24 hours were 1,044 +/- 750 mL in the clopidogrel within 4 days group, 528 +/- 250 mL in the clopidogrel 5 to 8 days group, and 573 +/- 329 mL in the clopidogrel more than 8 days group (p < 0.01). The mean total blood product transfusions were 12.2 +/- 15.4 U, 1.2 +/- 2.0 U, and 2.6 +/- 5.7 U, respectively (p < 0.001). Reoperation for bleeding was noted in 14.6%, 2.6%, and 1.7%, respectively (p = 0.002). The median hospital lengths of stay for the three groups were 9 days, 7 days, and 7 days, respectively (p = 0.018). There were no statistically significant differences in mortality rate, myocardial infarction, stroke, mediastinitis, or postoperative renal failure among the groups. Multivariable analysis revealed that clopidogrel within 0 to 4 days of operation was an independent predictor of transfusion requirements (OR 4.22, 95% confidence interval [CI] 2.07, 9.34, p = 0.001), intensive care unit (ICU) length of stay (OR 3.14, 95% CI 1.40, 7.04, p = 0.006), and total hospital length of stay (coefficient 7.65, se 2.41, p = 0.002).
Conclusions:
Clopidogrel within 4 days of coronary bypass surgery is associated with increased blood losses and reoperation for bleeding and, according to multivariable models, is an independent risk factor for increased transfusion requirements and prolonged ICU and hospital length of stay.
Related Concept Videos
01:23Peripheral Artery Disease V: Postoperative Nursing Management
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:27Coronary Artery Disease V: Interprofessional Care
01:27Peripheral Artery Disease III: Interprofessional Care
01:22Aneurysm IV: Nursing Management
01:28Acute Coronary Syndrome IV: Interprofessional Care